this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

Chemical Component Summary

NameTOBRAMYCIN
Identifiers(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
FormulaC18 H37 N5 O9
Molecular Weight467.51 g/mol
TypeNON-POLYMER
Isomeric SMILESNC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
InChIInChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N

Chemical Details

Formal Charge0
Atom Count69
Chiral Atom Count14
Chiral AtomsC11 C12 C13 C21 C23 C32 C33 C41 C42 C43 C51 C52 C53 C62
Bond Count71
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00684 Stereoisomeric match
NameTobramycin
Groups
  • approved
  • investigational
DescriptionAn aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is a 10% component of the antibiotic complex, nebramycin, produced by the same species. [PubChem]
Synonyms
  • 3'-Deoxykanamycin b
  • Nebramycin 6
  • Nebramycin factir 6
  • Nebramycin-Faktor 6
  • O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Salts
  • Tobramycin hydrochloride
  • Tobramycin Sulfate
Brand Names
  • Act Tobramycin Inhalation Solution
  • Aj-tobramycin
  • Apo-tobramycin
  • Bethkis
  • Jamp-tobramycin
Affected OrganismEnteric bacteria and other eubacteria
IndicationFor the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
PharmacologyTobramycin, an aminoglycoside antibiotic obtained from cultures of <i>Streptomyces tenebrarius</i>, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including <em>Pseudomonas aeruginosa</em>.
Mechanism of actionTobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.
Route of administration
  • Intramuscular; Intravenous
  • Intravenous
  • Ophthalmic
  • Oral
  • Oral; Respiratory (inhalation)
Categories
  • Aminoglycoside Antibacterials
  • Aminoglycosides
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antibacterials for Systemic Use
ATC-Code
  • S01AA12
  • J01GB01
AHFS-Code
  • 08:12.02
  • 52:04.04
CAS number32986-56-4

Drug Targets

NameSequence SearchPharmacological ActionActions
30S ribosomal protein S12MATVNQLVRKPRARKVAKSNVPALEACPQKRGVCTRVYTTTPKKPNSALR...yesinhibitor
unknowninhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682